NCT07491328|Recruiting
Liquid Biopsy in Paraneoplastic Neurological Syndromes
LiB-PNS
Loading search results
LiB-PNS
Sponsor study identifier
observational
60
1 country
1
Study Start
May 20, 2023
Actual (reported)Primary Completion
December 30, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 30, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH® System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients. Individuals with PNS and high- or intermediate-risk or GAD65-antibodies with a detectable tumor (PNS+T), PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor (PNS w/o T), and matched tumor patients without PNS (T w/o PNS) will be included in the study.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 30, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 20, 2023
Actual (reported)March 18, 2026
Actual (reported)March 24, 2026
Actual (reported)December 30, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 30, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
CTC detection
Detection of circulating tumor cells (CTCs) in the peripheral blood
Time of enrollment (BL)
ctDNA detection
Detection of circulating tumor DNA (ctDNA) in serum
Time of enrollment (BL)
CTC mutation profile
Time of CTC analysis (BL)
Patients with paraneoplastic neurological syndromes (PNS) and high- or intermediate-risk or GAD65-antibodies with a detectable tumor
PNS patients with high- or intermediate-risk or GAD65-antibodies without detectable tumor
Tumor patients without PNS
Analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the peripheral blood
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The study population will include patients with paraneoplastic neurological syndromes (PNS) and matched tumor patients without PNS.
Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf
Düsseldorf, 40225, Germany
Peripheral Blood Mononuclear Cells (PBMCs)
First Submitted
March 18, 2026
First Posted
March 24, 2026
Study Start
May 20, 2023
Actual (reported)Primary Completion
December 30, 2030
EstimatedContact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 30, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
March 24, 2026
Record last verified: 2026-03
All pseudonymized IPD that underlie the results in a publication.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: